# SU2C-SARC032 (NCT03092323)

> A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03092323
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sarcoma Alliance for Research through Collaboration
- Conditions: Soft Tissue Sarcoma of the Extremity
- Interventions: Pembrolizumab
- Enrollment: 126
- Primary outcome: Disease free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=su2c-sarc032-nct03092323

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03092323", "email": "<work email>"}; the inbox owner confirms by the emailed link.